Exact Sciences Corp (EXAS) Misses Q1 Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Exact Sciences (EXAS) Spec Buy Reiterated at Benchmark; Co. Anything But Revenue and Earnings Story
May 1, 2014 2:57 PM EDTBenchmark maintained a Speculative Buy rating on Exact Sciences (NASDAQ: EXAS) with a price target of $25.00. Comments follow Q1 results.
"Revenues were $0.3 Million and EPS was ($0.23). That being said, Exact Sciences is anything but a revenue and earnings storyat least for now. The company made significant progress on two fronts. The publication of the results of the DEEP-C Study in the New England Journal of Medicine highlighted what the benefits of the... More
